\documentclass[sigconf, nonacm]{acmart}
\usepackage{flushend}
\usepackage{graphicx}
\usepackage{ifthen}    %
\usepackage{xcolor}
\usepackage{tcolorbox}
\usepackage{etoolbox}  %
\usepackage{array}
\usepackage{makecell} %
\usepackage{booktabs}
\let\Bbbk\relax
\usepackage{multirow}
\usepackage{booktabs}
\usepackage{graphicx} %
\usepackage{subcaption} %
\usepackage{placeins} %
\usepackage{amssymb}
\usepackage{xspace}

\usepackage{adjustbox} %
\usepackage{algpseudocode}

\usepackage[ruled,vlined]{algorithm2e}
\usepackage{amsmath}
\usepackage{float}
\usepackage{colortbl}
\tcbuselibrary{breakable} %
\usepackage{tabularx} %
\usepackage{xstring}

\AtBeginDocument{%
  \providecommand\BibTeX{{%
    Bib\TeX}}}







\begin{document}

\title{K-Paths: Reasoning over Graph Paths for Drug Repurposing\\and Drug Interaction Prediction}

\author{Tassallah Abdullahi}
\email{tassallah_abdullahi@brown.edu}
\affiliation{%
  \institution{Brown University}
  \city{Providence}
  \state{RI}
  \country{USA}
}


\author{Ioanna Gemou}
\email{ioanna_gemou@brown.edu}
\affiliation{%
  \institution{Brown University}
  \city{Providence}
  \state{RI}
  \country{USA}
}

\author{Nihal V. Nayak}
\email{nihal_vivekanand_nayak@brown.edu}
\affiliation{%
  \institution{Brown University}
  \city{Providence}
  \state{RI}
  \country{USA}
}

\author{Ghulam Murtaza}
\email{ghulam_murtaza@brown.edu}
\affiliation{%
   \institution{Brown University}
  \city{Providence}
   \state{RI}
  \country{USA}
}

\author{Stephen H. Bach }
\email{stephen_bach@brown.edu}
\affiliation{%
  \institution{Brown University}
  \city{Providence}
  \state{RI}
  \country{USA}
}

\author{Carsten Eickhoff}
\authornote{co-corresponding authors.}
\email{carsten.eickhoff@uni-tuebingen.de}
\affiliation{%
  \institution{University of Tübingen}
  \city{Tübingen}
  \country{Germany}
}

\author{Ritambhara Singh}
\authornotemark[1]
\email{ritambhara@brown.edu}
\affiliation{%
  \institution{Brown University}
  \city{Providence}
  \state{RI}
  \country{USA}
}

\renewcommand{\shortauthors}{Abdullahi et al.}


\newcommand{\sys}{K-Paths\xspace}
\newcommand{\nihal}[1]{{\textcolor{magenta}{[Nihal: #1]}}}
\newcommand{\amina}[1]{\textcolor{purple}{\small \bf [Amina\#\arabic{amina}\stepcounter{amina}: #1]}}
\newcommand{\ioanna}[1]{\textcolor{blue}{\small \bf [Ioanna\#\arabic{ioanna}\stepcounter{ioanna}: #1]}}

\begin{abstract}
Drug discovery is a complex and time-intensive process that requires identifying and validating new therapeutic candidates. Computational approaches using large-scale biomedical knowledge graphs (KGs) offer a promising solution to accelerate this process. However, extracting meaningful insights from large-scale KGs remains challenging due to the complexity of graph traversal. Existing subgraph-based methods are tailored to graph neural networks (GNNs), making them incompatible with other models, such as large language models (LLMs). We introduce K-Paths, a retrieval framework that extracts structured, diverse, and biologically meaningful paths from KGs. Integrating these paths enables LLMs and GNNs to effectively predict unobserved drug-drug and drug-disease interactions. Unlike traditional path-ranking approaches, K-Paths retrieves and transforms paths into a structured format that LLMs can directly process, facilitating explainable reasoning. K-Paths employs a diversity-aware adaptation of Yen's algorithm to retrieve the K shortest loopless paths between entities in an interaction query, prioritizing biologically relevant and diverse relationships. Our experiments on benchmark datasets show that K-Paths improves the zero-shot performance of Llama 8.1B's F1-score by 12.45 points on drug repurposing and 13.42 points on interaction severity prediction. We also show that Llama 70B achieves F1-score gains of 6.18 and 8.46 points, respectively. K-Paths also improves the supervised training efficiency of EmerGNN, a state-of-the-art GNN, by reducing KG size by 90\% while maintaining strong predictive performance. Beyond its scalability and efficiency, K-Paths uniquely bridges the gap between KGs and LLMs, providing explainable rationales for predicted interactions. These capabilities show that K-Paths is a valuable tool for efficient data-driven drug discovery\footnote{code available at:\url{https://github.com/rsinghlab/K-Paths}}.


\end{abstract}

\begin{CCSXML}
<ccs2012>
   <concept>
       <concept_id>10010147.10010178.10010187</concept_id>
       <concept_desc>Computing methodologies~Knowledge representation and reasoning</concept_desc>
       <concept_significance>500</concept_significance>
       </concept>
 </ccs2012>
\end{CCSXML}

\ccsdesc[500]{Computing methodologies~Knowledge representation and reasoning}
\keywords{Knowledge graph reasoning, Drug Discovery, Large Language Models, Graph Neural Networks, Model Explainability}




\maketitle

\section{Introduction}
\input{introduction}

\section{Related Work}
\input{related_work}

\input{methods}

\section{Experiments} \label{sec:experiments}
\input{experiments}

\section{Results} \label{sec:results}
\input{results}

\section{Conclusion}
\input{conclusion}

\section*{Acknowledgements}
\input{acknowledgements}

\bibliographystyle{ACM-Reference-Format}
\bibliography{custom}

\appendix
\input{Appendix}

\end{document}
